There are a number of ongoing legal actions concerning patent rights that could affect the implementation of personalized medicine, such as patents on genes or tests. In an opinion piece at The Scientist, Courtenay Brinckerhoff, a partner at Foley & Lardner, writes that "the question being debated is whether these advances are most likely to flourish within the patent system or outside of it." Do patents, she asks, encourage innovation or prevent competition?

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Direct-to-consumer genetic testing companies have offered to test families separated at the southern US border, but that raises ethical issues.

CNBC reports that confirming a positive result from 23andMe's BRCA health report can be expensive.

The New York Times reports on a project to develop a tree DNA database to uncover illegal logging.

In PLOS this week: links between gut microbiome and colorectal cancer mutations, targeted sequencing uncovers genetic susceptibilities to epilepsy in Koreans, and more.